Cardio Diagnostics Holdings, Inc. announced its participation in the American College of Cardiology’s 74th Annual Scientific Session & Expo (ACC.25) from March 29-31, 2025. The company will showcase its enhanced PrecisionCHD test and its updated Actionable Clinical Intelligence (ACI) report.
The enhanced ACI report for PrecisionCHD is designed to provide clearer, more actionable clinical insights, leveraging six key methylation markers to give clinicians sharper visibility into modifiable drivers of coronary heart disease (CHD), including inflammation-related risk.
Additionally, Cardio Diagnostics will present new data on the power of PrecisionCHD's methylation biomarkers to predict mortality in patients with Acute Coronary Syndrome (ACS). This study highlights the superiority of methylation indices over angiographic methods for predicting mortality risk in ACS patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.